Chewing tablet of proton pump inhibitor

Abstract

The present invention relates to one kind of chewing tablet of proton pump inhibitor for treating gastric ulcer, duodenal ulcer, stomal ulcer and other indications. The chewing tablet contains proton pump inhibitor in 1-5 wt%, carbonate in 35-60 wt% and hydroxide in 35-60 wt%. The proton pump inhibitor is one selected from omeprazole, S-omeprazole, pantoprazole, lansoprazole, rabeprazole, leminoprazole, tenatoprazole and their salts. The biologically acceptable buffering agent is selected from sodium bicarbonate, sodium carbonate, magnesium carbonate, calcium carbonate and their mixture, preferably sodium bicarbonate. The hydroxide is selected from magnesium hydroxide, calcium hydroxide, aluminum hydroxide, sodium hydroxide and their mixture, preferably magnesium hydroxide.

Description

technical field [0001] A proton pump inhibitor chewable tablet of the present invention relates to a chewable tablet containing at least one proton pump inhibitor, at least one carbonate, and at least one hydroxide, used for treating gastric ulcer, twelve Indications for duodenal ulcer, anastomotic ulcer, reflux, esophagitis, Zoller-Ellison syndrome, etc. Background technique [0002] Digestive system disease is one of common frequently-occurring diseases, and wherein ulcer disease is the most common, and its total sickness rate accounts for 10~12% of total population approximately, and main onset age is 30~50 years old. There are 400,000 people in the United States suffering from peptic ulcers every year, mainly due to smoking, drinking, emotional stress, and drug stimulation (such as ASP, indomethacin, and peptic ulcer). The incidence rate of American men is 10%, and that of women is 5%. %. The gastrointestinal incidence rate is 5-10% in Japan and 12.3% in Germany. Acco...

AI Technical Summary

Problems solved by technology

[0005] Since proton pump inhibitors are easily degraded in an acidic environment, the usual oral preparations of proton pump inhibitors adopt enteric coating to prevent the active ingredient from degrading in gastric acid. The acid-suppressing effect of proton pump inhibitors is delayed, which is not conducive to timely treatment and rapid relief of patient suffering